Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer
NCT06015126Recruiting
- Start
- Oct 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of anlotinib and vinorelbine in breast cancer. Primary endpoint: Progression-Free Survival at 100 months. Started Oct 2022; status: recruiting.
02
Drugs
anlotinibvinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06015126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015126.